Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Thyroid Gland Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Head and Neck Cancer (562
)
Thyroid Gland Anaplastic Carcinoma (70
)
Thyroid Gland Medullary Carcinoma (61
)
Thyroid Gland Papillary Carcinoma (58
)
Thyroid Gland Follicular Carcinoma (25
)
Thyroid Gland Oncocytic Carcinoma (12
)
Head and Neck Cancer (562
)
Thyroid Gland Anaplastic Carcinoma (70
)
Thyroid Gland Medullary Carcinoma (61
)
Thyroid Gland Papillary Carcinoma (58
)
Thyroid Gland Follicular Carcinoma (25
)
Thyroid Gland Oncocytic Carcinoma (12
)
›
Associations
(359)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
cabozantinib capsule
Sensitive
:
A1
cabozantinib capsule
Sensitive: A1 - Approval
cabozantinib capsule
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Oncocytic Carcinoma
No biomarker
Thyroid Gland Oncocytic Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Oncocytic Carcinoma
No biomarker
Thyroid Gland Oncocytic Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: A1 - Approval
vandetanib
Sensitive
:
A1
vandetanib
Sensitive: A1 - Approval
vandetanib
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.